Oculus Innovative Sciences (OCLS) Gets Reimbursement Approval

September 10, 2009 · Filed Under General · Comments Off 

Oculus Innovative Sciences (OCLS) shares are up over 8% to $2.78, near their 52-week high. The stock’s period low is $.20.

The company announced that Noridian Administrative Services LLC, which is the pricing, data analysis and coding contractor for the Medicare program with respect to durable medical equipment, prosthetics, orthotics, and medical supplies, has assigned a Medicare HCPCS code for Oculus’ recently introduced Microcyn Skin & Wound HydroGel.

The HCPCS code #A6248 provides for 80% reimbursement of $17.05 per ounce. Reimbursement is provided for up to three ounces per month per patient wound.

Douglas A. McIntyre

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed